Login / Signup

Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.

Koichi HirataTakao TakeshimaFumihiko SakaiYotaro NumachiRyuji YoshidaReija KoukakisMiki HasebeDaishi YuiGabriel Paiva da Silva LimaSunfa Cheng
Published in: BMJ open (2023)
NCT03812224.
Keyphrases
  • open label
  • study protocol
  • clinical trial
  • phase ii
  • phase iii
  • randomized controlled trial
  • radiation therapy
  • drug induced
  • rectal cancer
  • smoking cessation